Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: Jongmans who wrote (33)	11/15/1999 1:39:00 AM
From: Larry Liebman	Read Replies (1) \| Respond to of 824

Continued positive clinical trial outcomes. Company reported that...."rheumatoid arthritis patients receiving a single dose of its anti-inflammatory complement inhibitor 5G1.1 showed a significant reduction in the signs and symptoms...compared to placebo-treated patients". The company is enrolling patients for an expanded Phase II trial. ALXN registered 2.5 million shares for a secondary on 10/20. When completed, there should be approximately 14 million shares out. With a current capitalization of <$200 million, a significant pipeline addressing major markets, and good balance sheet(after the offering), this company bears some due diligence.